NCT00865605View on ClinicalTrials.gov

Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions
Healthy
Interventions
DRUG

Halobetasol Propionate 0.05% Ointment, single exposure

A: Other Subjects received Alpharma/Purepac USHP formulated products

DRUG

Ultravate® 0.05% ointment, single exposure

Subjects received Bristol-Myers Squibb Company formulated products

Trial Locations (1)

92128

DermTech International, San Diego

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865605 - Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter